Ranexa generics — when can they launch?
Ranexa (RANOLAZINE) · Menarini Intl · 4 active US patents · 0 expired
Where Ranexa sits in the generic timeline
Long-dated protection: earliest active US patent for Ranexa extends to 2038 (~12 years out). Generic competition is at least 4 years away. Lifecycle moves (new formulations, label extensions, combination filings) typically execute 18-36 months ahead of cliff.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Formulation — 4 patents
Sample patent estate
Showing 4 of 4 active US patents. View full estate on the Ranexa drug page →
-
This patent protects an extended release multiparticulate composition of ranolazine for oral administration, which is bioequivalent to a marketed extended release tablet.USPTO title: Extended release multiparticulates of ranolazine
-
This patent protects an extended release multiparticulate composition of ranolazine for oral administration, which is bioequivalent to a marketed extended release tablet.USPTO title: Extended release multiparticulates of ranolazine
-
This patent protects an extended release multiparticulate composition of ranolazine for oral administration, which is bioequivalent to an existing extended release tablet.USPTO title: Extended release multiparticulates of ranolazine
-
This patent protects an extended release multiparticulate composition of ranolazine for oral administration, which is bioequivalent to a marketed extended release tablet.USPTO title: Extended release multiparticulates of ranolazine
Sources
- FDA Orange Book — patents listed against Ranexa (NDA filed 2006)
- Ranexa drug profile — full patent estate, indications, clinical trials, pricing
- Menarini Intl patent portfolio
- Patent cliff 2038 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Ranexa — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →